Title:
リガンド免疫原複合体を用いる処置方法
Document Type and Number:
Japanese Patent JP5632813
Kind Code:
B2
Abstract:
A method and pharmaceutical composition are provided for enhancing the endogenous immune response-mediated elimination of a population of pathogenic cells in a host animal wherein the pathogenic cells preferentially express, uniquely express, or overexpress a binding site for a particular ligand. The invention comprises administering the ligand conjugated to an immunogen to a host animal harboring the population of pathogenic cells. Antibodies, preexisting or administered to the host animal to establish a passive immunity, directed against the immunogen bind to the ligand-immunogen conjugate resulting in elimination of the pathogenic cells by the host's immune response. At least one additional therapeutic factor is administered selected from the group consisting of a cell killing agent, a tumor penetration enhancer, a chemotherapeutic agent, antimicrobial agent, a cytotoxic immune cell, and a compound capable of stimulating an endogenous immune response wherein the compound does not bind to the ligand-immunogen conjugate.
Inventors:
フィリップ・スチュアート・ロウ
インジュアン・ル
インジュアン・ル
Application Number:
JP2011225070A
Publication Date:
November 26, 2014
Filing Date:
October 12, 2011
Export Citation:
Assignee:
パーデュー・リサーチ・ファウンデイションＰＵＲＤＵＥ ＲＥＳＥＡＲＣＨ ＦＯＵＮＤＡＴＩＯＮ
International Classes:
A61K47/48; A61K35/14; A61K49/00; A61K38/00; A61K39/00; A61K39/02; A61K39/12; A61K39/385; A61K39/39; A61K39/395; A61K45/00; A61P31/00; A61P31/04; A61P31/10; A61P31/12; A61P33/00; A61P35/00; A61P35/02; A61P37/04; A61P43/00
Attorney, Agent or Firm:
Mitsuo Tanaka
Yamasaki 宏
Aoyama 葆
Yamasaki 宏
Aoyama 葆